Jazz Pharmaceuticals plc
JAZZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | -0.00 | 0.14 | -1.00 |
| FCF Yield | 5.74% | 1.55% | 5.16% | 5.17% |
| EV / EBITDA | 32.89 | -20.88 | 80.14 | 28.22 |
| Quality | ||||
| ROIC | 15.83% | -6.76% | -0.45% | 2.48% |
| Gross Margin | 77.11% | 88.88% | 88.35% | 88.17% |
| Cash Conversion Ratio | 1.89 | -0.12 | -4.64 | 2.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.10% | 2.79% | 2.83% | 3.60% |
| Free Cash Flow Growth | 355.40% | -74.19% | 1.46% | -0.69% |
| Safety | ||||
| Net Debt / EBITDA | -1.03 | -8.25 | 25.62 | 9.45 |
| Interest Coverage | 1.18 | -14.49 | -1.04 | 3.72 |
| Efficiency | ||||
| Inventory Turnover | 0.53 | 0.23 | 0.21 | 0.27 |
| Cash Conversion Cycle | 176.62 | 383.17 | 406.85 | 340.78 |